| Monitor for virilizing and adverse effects every 3 months for the first year, then every 6–12 months |
| Obtain baseline hematocrit and lipid profile and monitor at follow-up visits |
| Obtain baseline bone mineral density if a patient is at risk for osteoporosis; routine screening after age 60, or earlier if sex hormone levels consistently low |
| Monitor serum estradiol during the first 6 months and thereafter until uterine bleeding has ceased |
| Monitor serum testosterone at follow-up visits; target 300–1,000 ng/dL |
| Peak levels for parenteral testosterone measured 24–48 hrs after injection |
| Trough levels for parenteral testosterone measured before injection |
